for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aquestive Therapeutics Inc

AQST.OQ

Latest Trade

3.23USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

2.96

 - 

18.45

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.23
Open
--
Volume
--
3M AVG Volume
1.95
Today's High
--
Today's Low
--
52 Week High
18.45
52 Week Low
2.96
Shares Out (MIL)
25.04
Market Cap (MIL)
80.89
Forward P/E
-1.14
Dividend (Yield %)
--

Next Event

Q3 2019 Aquestive Therapeutics Inc Earnings Release

Latest Developments

More

Aquestive Therapeutics Q2 Revenue $11.1 Mln Vs $13.9 Mln

Intelgenx, Aquestive Therapeutics Enter Collaboration Agreement For Tadalafil

Aquestive Therapeutics Q1 Loss Per Share $0.59

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aquestive Therapeutics Inc

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant, Sympazan, and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108, and AQST-305, for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs, which includes Suboxone and APL-130277 for the treatment of opioid dependence, and Parkinson’s disease.

Industry

Biotechnology & Drugs

Contact Info

30 Technology Dr

+1.908.9411900

Executive Leadership

Santo Joseph Costa

Independent Chairman of the Board

Keith J. Kendall

President, Chief Executive Officer, Director

John T. Maxwell

Senior Vice President, Chief Financial Officer

Daniel Barber

Chief Operating Officer, Senior Vice President

Lori J. Braender

Senior Vice President, General Counsel, Secretary

Key Stats

1.83 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019(E)

0.0K
EPS (USD)

2018

-2.960

2019(E)

-2.844
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.50
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-304.56
Return on Equity (TTM)
-142.23

Latest News

Latest News

FDA declines to approve Aquestive's Viagra rival

Aquestive Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve its erectile dysfunction treatment and sought additional data.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up